Arcturus gets FDA go-ahead to begin Phase 2 trial for COVID-19 vaccine candidateMarket Watch • 01/04/21
Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United StatesBusiness Wire • 01/04/21
Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung DiseaseBusiness Wire • 12/30/20
Arcturus Reports Results From Early-Stage Testing of Its Coronavirus VaccineThe Motley Fool • 12/29/20
Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates (ARCT)Business Insider • 12/29/20
Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed ‘underwhelming'Market Watch • 12/29/20
Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical DataBusiness Wire • 12/28/20
3 COVID-19 Vaccine Stocks That Could Be the Biggest Winners in a Post-Pandemic WorldThe Motley Fool • 12/16/20